HLA-C - major histocompatibility complex, class I, C Gene
Also Known as MHC; HLAC; HLC-C; D6S204; PSORS1; HLA-JY3
Species: Homo sapiens
About HLA-C
This gene has 9 transcripts (splice variants), 1 gene allele, 553 orthologues, 22 paralogues and is associated with 3 phenotypes. Broad expression in lung (RPKM 536.7), bone marrow (RPKM 302.4) and 22 other tissues.
Summary
HLA-C belongs to the HLA class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane. Class I molecules play a central role in the immune system by presenting peptides derived from endoplasmic reticulum lumen. They are expressed in nearly all cells. The heavy chain is approximately 45 kDa and its gene contains 8 exons. Exon one encodes the leader peptide, exons 2 and 3 encode the alpha1 and alpha2 domain, which both bind the peptide, exon 4 encodes the alpha3 domain, exon 5 encodes the transmembrane region, and exons 6 and 7 encode the cytoplasmic tail. Polymorphisms within exon 2 and exon 3 are responsible for the peptide binding specificity of each class one molecule. Typing for these polymorphisms is routinely done for bone marrow and kidney transplantation. About 6000 HLA-C alleles have been described. The HLA system plays an important role in the occurrence and outcome of infectious diseases, including those caused by the malaria Parasite, the human immunodeficiency virus (HIV), and the severe acute respiratory syndrome coronavirus (SARS-CoV). The structural spike and the nucleocapsid proteins of the novel coronavirus SARS-CoV-2, which causes coronavirus disease 2019 (COVID-19), are reported to contain multiple Class I epitopes with predicted HLA restrictions. Individual HLA genetic variation may help explain different immune responses to a virus across a population.[provided by RefSeq, Aug 2020]
HLA-C Products (2)
| mRNA | Protein | Name |
|---|---|---|
| NM_001243042.1 | NP_001229971.1 | HLA class I histocompatibility antigen, C alpha chain precursor |
| NM_002117.6 | NP_002108.4 | HLA class I histocompatibility antigen, C alpha chain precursor |
| Molecular Function GO Annotation | Evidence | References | Source |
|---|---|---|---|
| enables TAP binding |
IDA
IDA: Inferred from direct assay
|
8617941 | GOA |
| enables peptide antigen binding |
IDA
IDA: Inferred from direct assay
|
22031944 | GOA |
| enables protein binding |
IPI
IPI: Inferred from physical interaction
|
12853576 | GOA |
| Biological Process GO Annotation | Evidence | References | Source |
|---|---|---|---|
| involved in antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent |
IDA
IDA: Inferred from direct assay
|
22031944 | GOA |
| Cellular Component GO Annotation | Evidence | References | Source |
|---|---|---|---|
| located in Golgi apparatus |
IDA
IDA: Inferred from direct assay
|
20946353 | GOA |
| part of MHC class I protein complex |
IDA
IDA: Inferred from direct assay
|
22031944 | GOA |
| located in cell surface |
IDA
IDA: Inferred from direct assay
|
9754572 | GOA |
| located in endoplasmic reticulum |
IDA
IDA: Inferred from direct assay
|
20946353 | GOA |
HLA-C Protein Structure
MHC_I: Class I Histocompatibility antigen, domains alpha 1 and 2 (26 - 203)
C1-set: Immunoglobulin C1-set domain (219 - 294)
MHC_I_C: MHC_I C-terminus (338 - 365)
- 0
- 100
- 200
- 300
- 366 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
HLA class I histocompatibility antigen, C alpha chain |
|
HLA-C Antibodies
| Cat. No. | Product Name | Application | Reactivity |
|---|---|---|---|
| HY-P83274 | HLA-C Antibody (YA3019) | WB, IP | Human, Mouse |
| HY-P83274A | HLA-C Antibody (YA3019)(PBS only) | WB, IP | Human, Mouse |
| HY-P84044 | HLA-C Antibody (YA3741) | IHC-P, ICC/IF, FC, ELISA | Human |
| HY-P84044A | HLA-C Antibody (YA3741)(PBS only) | IHC-P, ICC/IF, FC, ELISA | Human |
| HY-P84941 | HLA Class 1 ABC Antibody (YA4638) | ICC/IF, FC | Human |
Related Diseases
| Diseases | Alias | |
|---|---|---|
| Psoriasis 1 |
|
|
| Human Immunodeficiency Virus Type 1 |
|
|
| Severe Acute Respiratory Syndrome |
|
|
| Psoriasis |
|
|
| Psoriatic Arthritis |
|
|
| Pityriasis Rosea |
|
|
| B-Lymphoblastic Leukemia/Lymphoma With Recurrent Genetic Abnormality |
|
|
| Covid-19 |
|
|
| Glaucomatocyclitic Crisis |
|
|
| Spondylitis |
|
|
| Syphilis |
|
|
| Penis Carcinoma In Situ |
|
|
| Rubella |
|
|
| Arthritis |
|
|
| Behcet Syndrome |
|
|
| Alopecia Areata |
|
|
| Tonsillitis |
|
|
| Epstein-Barr Virus Hepatitis |
|
|
| Psoriasis 4 |
|
|
| Cholangitis, Primary Sclerosing |
|
|
| Severe Cutaneous Adverse Reaction |
|
|
| Skin Disease |
|
|
| Geographic Tongue |
|
|
| Colorectal Cancer, Hereditary Nonpolyposis, Type 8 |
|
|
| Malaria |
|
|
| Atrophic Glossitis |
|
|
| Fissured Tongue |
|
|
| Pre-Eclampsia |
|
|
| Beta-Thalassemia |
|
|
| Autoimmune Disease Of Skin And Connective Tissue |
|
|
| Spondyloarthropathy |
|
|
| Heart Disease |
|
|
| Leprosy 3 |
|
|
| Systemic Lupus Erythematosus |
|
|
| Celiac Disease 1 |
|
|
| Leukemia, Acute Myeloid |
|
|